SAN DIEGO, Oct. 13 /PRNewswire-FirstCall/ -- Alliance Pharmaceutical Corp.
(OTC Bulletin Board: ALLP) announces the appointment of Jack DeFranco to
President and Chief Operating Officer.
"I am pleased to announce the appointment of Jack DeFranco to President
and COO. Mr. DeFranco was with Alliance for 10 years prior to moving to IMCOR
as part of its acquisition of the Alliance imaging assets. He brings with him
a solid background and knowledge of Oxgent(TM) perfluorochemical emulsion, the
oxygen therapeutic market and the personnel within the Company," said Duane
Roth, Alliance Chairman and CEO.
Mr. DeFranco was Vice President of Business Development and Marketing with
Alliance for 10 years prior to serving as Senior Vice President and COO of
IMCOR Pharmaceutical Co. He has held various management positions in business
development, marketing and sales with Smith & Nephew and Johnson and Johnson.
In his career he has launched over 20 medical products, many of which related
to blood transfusion safety. He has also been instrumental in negotiating
over $100M in corporate partnerships. Mr. DeFranco holds a BS in Biology from
Stephen F. Austin University and an MBA and a Masters in Finance from
Fairleigh Dickenson University.
About Alliance Pharmaceutical Corp.
Alliance Pharmaceutical Corp., founded in 1989, is a development-stage
pharmaceutical company that is currently focused on developing its lead
product, Oxygent. Alliance is currently the only company that has advanced a
synthetic perfluorochemical (PFC) emulsion-based oxygen therapeutic into
late-stage multi-center international clinical trials in both Europe and North
America. Alliance is developing Oxygent as an intravascular oxygen
therapeutic, based on its proprietary PFC and surfactant technologies.
Except for historical information, the matters set forth in this release
are forward-looking statements that are subject to risks and uncertainties
that could cause actual results to differ materially from those set forth
herein, including the uncertainties associated with the conduct of preclinical
or clinical studies. Alliance refers you to cautionary information contained
in documents Alliance files with the Securities and Exchange Commission from
time to time, including the last Form 10-KSB and Form 10-QSB, and those risk
factors set forth in the most recent registration statement on Form SB-2 (File
No. 333-119428). Alliance is under no obligation (and expressly disclaims any
obligation) to update or alter its forward-looking statements, whether as a
result of new information, future events, or otherwise.
Contact for further information:
Corporate Communications
Alliance Pharmaceutical Corp.
San Diego, CA
(858) 410-5275
SOURCE Alliance Pharmaceutical Corp.
 back to top
Related links:
http://www.allp.com
CONTACT:
Corporate Communications of Alliance
Pharmaceutical Corp., +1-858-410-5275
|
